Amylyx Pharmaceuticals (AMLX) EBITDA Margin Growth (1y) (2022 - 2024)
Powered by 
Analysis
Amylyx Pharmaceuticals (AMLX) EBITDA Margin Growth (1y) (2022 - 2024) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 210.97 Bn | 196.98 Bn | 7.24 Bn | 602.00 |
| 2 | Gilead Sciences | 180.98 Bn | 177.80 Bn | 6.22 Bn | -16,814.00 |
| 3 | Vertex Pharmaceuticals | 132.09 Bn | 124.24 Bn | 2.84 Bn | -143.00 |
| 4 | Regeneron Pharmaceuticals | 82.56 Bn | 74.57 Bn | 3.93 Bn | 78.00 |
| 5 | Argenx Se | 61.71 Bn | 56.53 Bn | 1.37 Bn | 1,135.00 |
| 6 | Moderna | 54.60 Bn | 49.46 Bn | 52.00 Mn | 7,666.00 |
| 7 | Alnylam Pharmaceuticals | 34.02 Bn | 30.71 Bn | 992.69 Mn | 2,002.00 |
| 8 | Biogen | 31.25 Bn | 29.97 Bn | 1.96 Bn | -2,881.00 |
| 9 | Roivant Sciences | 29.76 Bn | 29.76 Bn | 1.16 Mn | -1.23 Mn |
| 10 | Amylyx Pharmaceuticals | 3.64 Bn | 3.64 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2024 | 639,036.00 |
| Sep 30, 2024 | -1.82 Mn |
| Jun 30, 2024 | -747,765.00 |
| Mar 31, 2024 | -13,490.00 |
| Dec 31, 2023 | 20,554.00 |
| Sep 30, 2023 | 1.59 Mn |
| Sep 30, 2022 | -780,816.00 |